Valuation : Stoke Therapeutics, Inc.

Market Cap 1.92B 1.66B 1.56B 1.42B 2.66B 182B 2.67B 18.4B 7.14B 93.18B 7.22B 7.07B 300B P/E 2026 *
-8.22x
P/E 2027 * -8.29x
Enterprise Value 1.72B 1.48B 1.39B 1.27B 2.38B 162B 2.39B 16.45B 6.38B 83.29B 6.46B 6.32B 268B EV / Sales 2026 *
53.7x
EV / Sales 2027 * 37.5x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week-5.72%
Current month-4.46%
1 month-6.64%
3 months-0.67%
6 months-13.97%
Current year-6.08%
1 week 29.14
Extreme 29.145
32.18
1 month 29.14
Extreme 29.145
33.94
Current year 25.21
Extreme 25.21
40.22
1 year 20.32
Extreme 20.32
40.22
3 years 3.35
Extreme 3.35
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 54 01/06/2014
Chief Executive Officer 60 19/03/2025
Director of Finance/CFO 49 07/05/2024
Director TitleAgeSince
Chairman 65 01/07/2015
Director/Board Member 67 01/06/2014
Director/Board Member 72 01/09/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Technology Officer

-5,545 0.0094%
18/08/26 Sell

Chief Technology Officer

-4,767 0.0081%
18/08/26 Sell

Director

-12,567 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%-5.72%+44.15%+444.97% 1.92B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.89%-0.09%+70.73%+146.89% 27.69B
Weighted average by Cap. -1.03%+0.07%+89.08%+130.28%

Financials

2026 *2027 *
Net sales 32.02M 27.56M 25.93M 23.68M 44.31M 3.02B 44.43M 306M 119M 1.55B 120M 118M 5B 44.83M 38.57M 36.29M 33.15M 62.02M 4.23B 62.19M 429M 166M 2.17B 168M 165M 7B
Net income -241M -207M -195M -178M -333M -22.72B -334M -2.3B -893M -11.66B -904M -884M -37.56B -261M -225M -212M -193M -361M -24.67B -362M -2.5B -970M -12.66B -981M -960M -40.77B
Net Debt -204M -176M -165M -151M -283M -19.28B -283M -1.95B -758M -9.89B -767M -750M -31.87B -242M -208M -196M -179M -335M -22.86B -336M -2.32B -899M -11.73B -909M -889M -37.78B
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
04/09/26 $29.81 -0.60% 714,062
03/09/26 $29.99 -1.67% 512,255
02/09/26 $30.50 -1.26% 631,317
01/09/26 $30.89 -0.99% 727,504
31/08/26 $31.20 -1.33% 1,116,087
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
29.81USD
Average target price
46.46USD
Spread / Average Target
+55.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STOK Stock